Trials / Unknown
UnknownNCT04882956
BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration
Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.
Detailed description
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intravitreal injection | Brolucizumab-Dbll intravitreal injection |
| DRUG | intravitreal injection | Aflipercept intravitreal injection |
Timeline
- Start date
- 2020-08-05
- Primary completion
- 2021-12-01
- Completion
- 2022-03-01
- First posted
- 2021-05-12
- Last updated
- 2021-05-12
Locations
1 site across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT04882956. Inclusion in this directory is not an endorsement.